We perform an econometric assessment of the role that pharmaceutical innovation-the introduction and use of new drugs-has played in reducing the burden of disease in Canada, by investigating whether diseases for which more new drugs were launched had larger subsequent reductions in disease burden. Since utilization of a drug reaches a peak about 12-14 years after it was launched, we allow for considerable lags in the relationship between new drug launches and the burden of disease.
Introduction
The health status of Canadians has improved during the 21st century. Life expectancy at birth increased from 79.24 years in 2000 to 82.14 years in 2015. Also, the age-standardized rate of potential years of life lost before age 75 1 per 100,000 population declined from 4214 during 1999-2003 to 3601 during 2009-2013-a 15% decline (Statistics Canada (2018a) ).
Some researchers have argued that biomedical innovation has been the principal cause of recent improvements in health. Fuchs (2010) said that "since World War II … biomedical innovations (new drugs, devices, and procedures) have been the primary source of increases in longevity," although he did not provide evidence to support this claim. Cutler, Deaton, and Lleras-Muney (2006) performed a survey of a large and diverse literature on the determinants of mortality, and "tentatively identif[ied] the application of scientific advance and technical progress (some of which is induced by income and facilitated by education) as the ultimate determinant of health." They concluded that "knowledge, science, and technology are the keys to any coherent explanation" of mortality. Other research has shown that most technological progress is "embodied": to benefit from technological progress, people must use new products and services. 2 Most scholars agree with Jones' (1998, pp. 89-90) statement that "technological progress is driven by research and development (R&D) in the advanced world." In 1997, the medical substances and devices sector was the most R&D-intensive 3 major industrial sector in the U.S.: almost twice as R&D-intensive as the next-highest sector (information and electronics), and three times as R&D-intensive as the average for all major sectors. (National Science Foundation (2017) ). According to Dorsey et al. (2010) , in 2008, 88% of privately-funded U.S. biomedical research expenditure was funded by pharmaceutical and biotechnology firms; the remaining 11% was funded by medical device firms.
The purpose of this study is to assess econometrically the role that pharmaceutical innovation-the introduction and use of new drugs-has played in reducing the burden of disease in Canada. During the period 1980-2016, drugs with 1404 new ATC codes were launched in Canada: about 39 new ATC codes per year, on average. 4 For reasons discussed below, there is likely to be a substantial lag between the launch of a new drug and its maximum impact on the burden of disease, so we will allow for considerable lags in the relationship between new drug launches and the burden of disease.
The analysis will be performed using a difference-in-differences (or two-way fixed effects) research design: we will investigate whether diseases for which more new drugs were launched had larger subsequent reductions in disease burden. This design controls for the effects of general economic and societal factors (e.g. income, education, and behavioural risk factors 5 ), to the extent that those effects are similar across diseases, e.g. smoking increases mortality from respiratory and cardiovascular disease as well as lung cancer, and education reduces mortality from all diseases.
The number of new drug launches varied considerably across diseases. 6 Fig. 1 shows the number of chemical substances used to treat 5 diseases that had ever been launched in Canada during the period 1980-2016. These five diseases were selected because an identical number of-six-chemical substances had been launched for each disease by the year 1980. During the next 36 years, 14 new drugs for treating ovary cancer were launched; between 5 and 7 new drugs for treating gonorrhea, bladder cancer, and bipolar disorder were launched; only one new drug for treating gout was launched.
The primary measure of disease burden we will analyze is the number of disability-adjusted life-years (DALYs) lost, as defined and measured by the World Health Organization (2018a). The DALY is a summary measure that combines time lost through premature death and time lived in states of less than optimal health, loosely referred to as "disability". The DALY is a generalization of the well-known potential Years of Life Lost measure (YLLs) to include lost good health. One DALY can be thought of as one lost year of 'healthy' life, and the measured disease burden is the gap between a population's health status and that of a normative reference population. DALYs for a specific cause are calculated as the sum of the YLLs from that cause and the years of healthy life lost due to disability (YLDs) for people living in states of less than good health resulting from the specific cause. The YLLs for a cause are essentially calculated as the number of cause-specific deaths multiplied by a loss function specifying the years lost for deaths as a function of the age at which death occurs. 7 Table 1 shows data on the number of DALYs lost (due to all causes) and population, by age group, in Canada in 2000 and 2016. Almost 9 million DALYs were lost in 2016. As shown in row 8, the crude DALY rate (DALYs lost per 100 population) declined by just 2% between 2000 and 2016. However, the DALY rate generally increases sharply with age (e.g., in 2016, the rate among people age 70 and over was about 3 times as high as the rate among people age 50-59), and the Canadian population is aging: the fraction of the population that was age 60 and over increased from 17% in 2000 to 23% in 2016. The age-standardized DALY rate declined by 14% between 2000 and 2016, and the rates among people age 60 and over declined by 20-22%. We will analyze the impact of new drug launches on the age-standardized DALY rate and on its two components: the age-standardized YLL and YLD rates. We will also analyze the impact of new drug launches on the number of hospital discharges and on the average length of hospital stays.
In the next section, we will describe the econometric model that we will use to assess the role that pharmaceutical innovation has played in reducing the burden of disease in Canada during the period 2000-2016. The data sources used to estimate this model are discussed on Section III. Empirical results are presented in Section IV. Some implications of the estimates are discussed in Section V. Section VI provides a summary.
Methods
To assess the impact that pharmaceutical innovation had on the burden of disease, we will estimate models based on the following 2way fixed effects equation 8 :
where Y dt is one of the following variables: (2015) . 5 The trend in one behavioural risk factor-obesity-may have increased the burden of disease. Between 2003 and 2014, the fraction of Canadian men whose reported height and weight classified them as obese increased from 16.0% to 21.8%; the fraction of Canadian women whose reported height and weight classified them as obese increased from 14.5% to 18.7% (Statistics Canada (2018b)). 6 Many drugs are used to treat multiple diseases: 50% of drugs are used to treat 2 or more diseases, 25% of drugs are used to treat 3 or more diseases, and 14% of drugs are used to treat 4 or more diseases. 7 To estimate YLDs for a particular cause in a particular time period, the number of incident cases in that period is multiplied by the average duration of the disease and a weight factor that reflects the severity of the disease on a scale from 0 (perfect health) to 1 (dead). The 'valuation' of time lived in non-fatal health states formalizes and quantifies the loss of health for different states of health as disability weights. In the standard DALYs reported by the original Global Burden of Disease study and in subsequent WHO updates, calculations of YLDs and YLLs used an additional 3% time discounting and non-uniform age weights that give less weight to years lost at young and older ages (Murray (1996) ). Using discounting and age weights, a death in infancy corresponds to 33 DALYs, and deaths at ages 5-20 years to around 36 DALYs. 8 In addition to estimating models based on the log-log specification (eq. (1)), and the number of chemical substances ever launched may be considered a measure of the stock of pharmaceutical "ideas." Jones (2002) argued that "long-run growth is driven by the discovery of new ideas throughout the world." 10 The log-log specification of eq. (1) incorporates the assumption of diminishing marginal productivity of chemical substance launches: each additional chemical substance launch for a medical condition results in a diminishing absolute reduction in disease burden. If the cost of chemical substance launches for different diseases were equal, it would be socially optimal to equalize the absolute reductions in disease burden across diseases. A small percentage reduction in the burden of a high-burden disease would be as valuable as a large percentage reduction in the burden of a low-burden disease. Estimates based on eq. (1) will provide evidence about the impact of the launch of drugs for a disease on the burden of that disease, but they will not capture possible spillover effects of the drugs on the burden of other diseases. These spillovers may be either positive or negative. For example, the launch of cardiovascular drugs could reduce mortality from cardiovascular disease, but increase mortality from the "competing risk" of cancer. On the other hand, the launch of drugs for mental disorders could reduce mortality from other medical conditions. Prince et al. (2007) argued that "mental disorders increase risk for communicable and non-communicable diseases, and contribute to unintentional and intentional injury. Conversely, many health conditions increase the risk for mental disorder, and comorbidity complicates helpseeking, diagnosis, and treatment, and influences prognosis."
Due to data limitations, ln(CUM_DRUG d,t-k ) is the only diseasespecific, time-varying regressor in eq. (1). If the data were available, we would like to include other regressors in eq. (1), including (1) disease incidence, and (2) the number of non-pharmaceutical medical innovations (e.g. medical device innovations) that had been launched in Canada. However, there is good reason to believe that failure to control for those variables is unlikely to result in overestimation of the magnitude of β k ; exclusion of those variables may even result in underestimation of the magnitude of β k . Higher disease incidence is likely to result in both higher disease burden and a larger number of chemical substance launches:
Previous studies have shown that both innovation (the number of drugs developed) and diffusion (the number of drugs launched in a country) depend on market size. Acemoglu & Linn, n.d. found "economically significant and relatively robust effects of market size on innovation." Danzon, Wang, and Wang (2005) found that "countries with lower expected prices or smaller expected market size experience longer delays in new drug access, controlling for per capita income and other country and firm characteristics" (emphasis added).
Although incidence data are not available for most diseases, annual incidence data for the period 1992-2010 are available for 31 cancer sites (breast, lung, etc.). As expected, there is a significant positive correlation across cancer sites between ln(CASES st ) (where CASES st = the number of patients diagnosed with cancer at cancer site s in year t) and ln(CUM_DRUG st ) (where CUM_DRUG st = the number of chemical substances to treat cancer at site s that had ever been launched by the end of year t). But estimates of the equation ln (CUM_DRUG st ) = π ln(CASES st ) + α s + δ st + ε st indicate that the growth rate of CUM_DRUG is uncorrelated across cancer sites with the growth rate of incidence. This suggests that estimates of β k in eq. (1) are unlikely to be biased by the omission of incidence in that equation.
Failure to control for non-pharmaceutical medical innovation (e.g. innovation in diagnostic imaging, surgical procedures, and medical devices) is also unlikely to bias estimates of the effect of pharmaceutical innovation on the burden of disease, for two reasons. First, as noted earlier, 88% of privately-funded U.S. funding for biomedical research came from pharmaceutical and biotechnology firms (Dorsey et al. (2010) ). 11 Second, previous research based on U.S. data (Lichtenberg (2014a; 2014b) ) indicated that non-pharmaceutical medical innovation is not positively correlated across diseases with pharmaceutical innovation.
The dependent variable of eq. (1) is the log of the level of disease burden in year t. We will use data for two years: 2000 and 2016. Substituting those two values of t into eq. (1) yields: 2000 (2)
ln(Y d,2016 ) = β k ln (CUM_DRUG d,2016-k 
Subtracting eq. (2) from eq. (3) yields:
where
Eq. (4) is a simple regression of the 2000-2016 growth in the burden of disease d on the growth in the number of drugs that were used to treat disease d that had ever been launched k years earlier. 12 To address the issue of heteroskedasticity, 13 eq. (4) will be estimated by weighted least squares, weighting by (Y d,2000 + Y d,2016 )/2.
The mean (across all medical conditions) 2000-2016 log change in disease burden from drugs launched k years earlier is Δ k = β k * mean (Δln(CUM_DRUG_k d )). The (absolute) reduction in 2016 disease burden from drugs launched between 2000 -k and 2016 -k is (∑ d Y d,2016 ) * (1 -(1/exp(Δ k ))).
We will estimate 63 (= 3 * 21) versions of eq. (4): one for each of the three measures of disease burden (DALY, YLL, and YLD) for 21 different lag values (k = 0, 1, …, 20). There is likely to be a substantial lag between the launch of a new drug and its maximum impact on the burden of disease. Utilization of recently-launched drugs tends to be much lower than utilization of drugs launched many years earlier. Evidence about the shape of the drug-age (number of years since launch) drug-utilization profile can be obtained by estimating the following equation: ln(N_SU mn ) = ρ m + π n + ε mn (5) where N_SU mn = the number of standard units of molecule m sold in Canada n years after it was first launched (n = 0, 1, …, 20) ρ m = a fixed effect for molecule m π n = a fixed effect for age n 10 The discovery of new ideas could increase economic output for two different reasons. First, output could simply be positively related to the quantity (and variety) of ideas ever discovered. Second, output could be positively related to the (mean or maximum) quality of ideas ever discovered, and new ideas may be better (of higher quality), on average, than old ideas. 11 Much of the rest came from the federal government (i.e. the NIH), and new drugs often build on upstream government research (Sampat and Lichtenberg (2011) ). The National Cancer Institute (2017) says that it "has played a vital role in cancer drug discovery and development, and, today, that role continues." 12 The parameter δ′ in eq. (4) is an estimate of the mean log change in disease burden in the absence of any drug launches between 2000 -k and 2016 -k. 13 Percentage deviations of observations with low disease burden means exhibit much greater variance and volatility than percentage changes of observations with high average disease burden means.
The expression exp(π n -π 14 ) is a "relative utilization index": it is the mean ratio of the quantity of a drug sold n years after it was launched to the quantity of the same drug sold 14 years after it was launched. We estimated eq. (5), using annual data for the period 2007-2017 on 721 molecules. Estimates of the "relative utilization index" are shown in Fig. 2 . These estimates indicate that utilization of a drug reaches a peak about 12-14 years after it was launched. It is used about twice as much then as it was 4 years after launch 14 Due to gradual diffusion of new drugs, the maximum impact of a drug on disease burden is likely to occur many years after it was launched, but the peak effect could occur either more than or less than 12-14 years after launch. The lag might be longer because some drugs for chronic diseases (e.g. statins) may have to be consumed for several years to achieve full effectiveness. But the lag might be shorter because the impact of a drug on disease burden is likely to depend on its quality (or effectiveness) as well as on its quantity (utilization), and drugs launched more recently are likely to be of higher quality than earliervintage drugs. 15, 16 As mentioned earlier, in addition to analyzing the impact of new drug launches on DALYs, we will analyze their impact on the number of hospital discharges and on the average length of hospital stays, by estimating the following equations:
Δln(ALOS d ) = β k Δln(CUM_DRUG_k d ) + δ'+ ε d '
Where.
Δln ( Eqs. (6) and (7) will be estimated by weighted least squares, weighting by (DISCHARGES d,2000 + DISCHARGES d,2016 )/2.
Data sources
Disease burden data. Age-standardized rates of DALY, YLL, and YLD, by disease and year, were constructed using data obtained from the World Health Organization's Disease Burden Database (World Health Organization (2018b)). 17 The disease classification used in the Disease Burden Database is described in Annex Table A 14 The estimate of a 12-14 year lag from drug launch to peak drug utilization in Canada is 4 years longer than the average 8-10 year lag in 22 countries (Australia, Austria, Belgium, Brazil, Canada, Switzerland, Chile, Colombia, Germany, Ecuador, Spain, Finland, France, United Kingdom, Ireland, Italy, Japan, Mexico, Portugal, Singapore, Sweden, and the U.S.) estimated in Lichtenberg (2019) . In that study, data on drug launch dates were obtained from a different data source: the IQVIA New Product Focus database. 15 Grossman and Helpman (1993) argued that "innovative goods are better than older products simply because they provide more 'product services' in relation to their cost of production." Bresnahan and Gordon (1996) stated simply that "new goods are at the heart of economic progress," and Bils (2004) said that "much of economic growth occurs through growth in quality as new models of consumer goods replace older, sometimes inferior, models." As noted by Jovanovic and Yatsenko (2012) , in "the Spence-Dixit-Stiglitz tradition … new goods [are] of higher quality than old goods." 16 The impact on mortality may depend on the interaction (quantity * quality)
of the two variables. The mortality impact will increase with respect to drug age (footnote continued) (time since launch) if the rate of increase of quantity with respect to age is greater than the rate of decline of quality with respect to age; otherwise the mortality impact will decline. 17 These data may also be obtained from the Global Health Data Exchange (2019). (2018)) was used to determine the years in which (WHO ATC 5th-level) chemical substances first received market authorization in Canada.
Drug indications data. Indications (coded by ICD-10) of chemical substances were obtained from Theriaque, a database produced by the French Centre National Hospitalier d'Information sur le Médicament (2018) . 18 The number of (WHO ATC5) chemical substances ever launched, by cause, during 1980-2016 are shown in Appendix Table 2 .
Drug utilization and expenditure data. Data on the quantity (number of standard units) and value (in USD) of prescription drugs sold in Canada, by chemical substance and year (2007) (2008) (2009) (2010) (2011) (2012) (2013) (2014) (2015) (2016) (2017) were obtained from the IQVIA MIDAS database.
Cancer incidence data. Data on the number of new cases of primary cancer, by cancer site and year, were obtained from Statistics Canada (2018c).
Hospitalization data. Data on the number of hospital discharges and average length of stay, by diagnosis, in 2000 and 2016, were obtained from the OECD Health Statistics database (OECD (2018a)). The disease classification scheme is provided in OECD (2018b). The number of hospital discharges and average length of stay (in days), by cause, in 2000 and 2016 are shown in Appendix Table 3 .
Results
Estimates of β k parameters of eq. (4) are shown in Table 2 . In Panel A of Table 2 , the dependent variable is Δln(DALY d ) = ln (DALY d,2016 / DALY d,2000 ). The estimate in each row of the table is from a separate model. Rows 1-21 show estimates for assumed values of 0, 1, 2, …, 20 years of the lag (k) from drug launch to disease burden. The point estimates and 95% confidence intervals are also plotted (on an inverted scale) in Panel A of Fig. 3 , where solid markers denote significant (pvalue < .05) estimates and hollow markers represent insignificant estimates. For k ≤ 8, only 3 of the 9 estimates are statistically significant. This is not surprising since, as discussed earlier, utilization of recentlylaunched drugs tends to be quite low, and there may also be a lag from drug utilization to disease burden reduction. However, for k ≥ 9, all 12 β k estimates are negative and statistically significant: the number of DALYs lost is significantly inversely related to the number of drugs that had ever been launched 9-20 years earlier. The magnitude of the estimates tends to increase as k increases, until k = 15, when it starts to decline. The launch of a drug had the largest (most negative) impact on the number of DALYs lost 15 years after it was launched.
Panel A of Fig. 4 shows a comparison of the relative utilization and DALY β k estimate profiles. Utilization of a drug tends to rise until 12 years after launch, remains stable for 3 years, and then starts to decline. The β k estimates exhibit some volatility in years 0-6, but then generally increase in magnitude until year 15, and begin to decline the year after utilization begins to decline. The correlation between these two profiles is highly statistically significant (correlation = −0.58; p-value = .006). Fig. 5 is a bubble plot depicting the relationship across diseases between the 1985-2001 percentage increase in the number of drugs ever launched, and the 2000-2016 percentage change in the age-standardized DALY rate. It is clear from the figure that ischemic heart disease is a highly influential observation. Although the fact that an observation is influential does not necessarily mean that it should be excluded, we estimated the model when that observation was excluded. Exclusion of that observation reduced the point estimate of β 15 by 36% (from −0.414 to −0.265), but the estimate remained highly significant (t-value = 4.93; p-value < .0001). 19 Another apparently influential observation is diabetes. This observation is weakening the relationship between drug launches and DALY reduction: despite a large percentage increase in the number of diabetes drugs, the burden of diabetes did not decline by an unusually large amount. This may be due to a significant increase in the prevalence of diabetes. 20 Appendix Fig. 1 shows that the prevalence of diabetes in Canada increased significantly between 2000/2001 and 2008. When we exclude both diabetes and ischemic heart disease from the sample, the point estimate of β 15 (−0.385) is very close to the estimate reported in row 16 of Table 2 , and is highly significant (tvalue = 5.69; p-value < .0001).
We also estimated an alternative functional form (semi-logarithmic as opposed to log-log) of the relationship between drug launches and subsequent DALY reduction. These estimates are shown in Appendix Table 4 . Twenty of the 21 coefficients are negative and significant. There is little evidence of an inverted U-shaped profile, and the maximum magnitude of the effect (β k * mean (regressor)) in the semilogarithmic model is only 38% as large as the maximum magnitude of the effect in the log-log model. But the fit of the semi-logarithmic model is inferior to the fit of the log-log model. When we include both ln (CUM_DRUG d,2001 /CUM_DRUG d,1985 ) and (CUM_DRUG d,2001 -CUM_-DRUG d,1985 ) in the model, as suggested by Davidson and MacKinnon (1981) , the coefficient on the former regressor is significant, but the coefficient on the latter regressor is not. This indicates that the log-log functional form is more appropriate than the semi-logarithmic functional form. 21 Now we will briefly summarize estimates of models of the two components of DALY, YLL and YLD. 22 In Panel B of Table 2 , the dependent variable is Δln(YLL d ) = ln (YLL d,2016 /YLL d,2000 ). Rows 22-42 show estimates for assumed values of 0, 1, 2, …, 20 years of the lag (k) from drug launch to disease burden. The point estimates and 95% confidence intervals are also plotted (on an inverted scale) in Panel B of Fig. 3 . For k ≤ 10, only 1 of the 11 estimates is statistically significant. However, for k ≥ 11, all 10 β k estimates are negative and statistically significant: the number of YLLs is significantly inversely related to the number of drugs that had ever been launched 11-20 years earlier. Once again, the magnitude of the estimates tends to increase as k increases, until k = 15, when it starts to decline. The launch of a drug had the largest (most negative) impact on the number of YLLs lost 15 years after it was launched. Panel B of Fig. 4 shows a comparison of the relative utilization and YLL β k estimate profiles. Like the DALY β k estimates, the YLL β k estimates exhibit some volatility in years 0-6, but then generally increase in magnitude until year 15, and begin to decline the year after utilization begins to decline. The correlation between these two profiles is again highly statistically significant (correlation = −0.78; pvalue < .001).
In Panel C of Table 2 , the dependent variable is Δln(YLD d ) = ln (YLD d,2016 /YLD d,2000 ). The point estimates and 95% confidence intervals are also plotted (on an inverted scale) in Panel C of Fig. 3 . For k ≤ 8, none of the 9 estimates are statistically significant. For 9 ≤ k ≤ 14, 3 out of 6 β k estimates are negative and significant. For 15 ≤ k ≤ 20, 6 out of 6 β k estimates are negative and significant. This indicates that the number of years lost due to disability was reduced by 18 Theriaque provides data only on labeled indications; it does not provide data on off-label indications. 19 If all 6 cardiovascular diseases are removed from the sample, the point estimate of β 15 is −0.209 and is still highly significant (t-value = 4.02; pvalue = .0001). 20 This may be related to the rise in obesity described earlier. 21 Also, estimates of the semi-logarithmic functional form are more likely to be influenced by the disease classification/aggregation scheme than estimates of the log-log functional form. 22 As shown in Appendix Table 2 imply that most of the DALY reduction from new drug launches was due to a reduction in YLL. The estimates of β 15 in rows 16, 37, and 58 imply that new drug launches during 1986-2001 reduced DALYs in 2016 by 21% (= 1 -exp (-0.231)), reduced YLLs in 2016 by 28%, and reduced YLDs in 2016 by 3%. 23 There will be additional discussion of the magnitudes of these effects in the next section.
The last estimates we will present are estimates of β k from the hospital discharges and average length of stay equations, eqs. (6) and (7) . Panel A of Table 3 shows estimates of β k from the hospital discharges equation, eq. (6). None of the estimates are statistically significant; we see no evidence that new drug launches reduced the number of people discharged from (or admitted to) hospitals. However, since there is strong evidence that new drug launches reduced mortality, they may have increased the number of people "at risk" of being hospitalized, so new drug launches may have reduced the number of hospital discharges per person at risk of being hospitalized.
Panel B of Table 3 shows estimates of β k from the average length of hospital stay equation, eq. (7). All 21 estimates are negative and highly significant (p-value ≤ .011), indicating that medical conditions for which there were more new drug launches had smaller increases in average length of stay (ALOS). 24 In contrast to the DALY and YLL estimates, the magnitudes of the ALOS estimates are larger for more recent drug launches. Perhaps uptake of new drugs is more rapid among hospitalized patients than it is among other patients. However, the overall impact of new drug launches (β k * mean(Δln(CUM_DRUG_k))) is highest for k = 16: new Table 3 indicates that those drug launches reduced ALOS in 2016 by 16% (= 1 -exp(-0.178)).
Discussion
The estimates of the DALY model shown in Panel A of Table 2 and Figs. 3 and 4 , in conjunction with other data, may be used to calculate the reduction in DALYs lost in 2016 attributable to previous drug launches and the average cost per DALY gained. DALYs are most significantly inversely related to the number of drugs that had ever been launched 15 years earlier. The estimate of β 15 in row 16 of Table 2 indicates that drugs launched during 1986-2001 reduced the mean 2000-2016 log change in DALYs lost by −0.231. This implies that, in the absence of those drug launches, DALYs lost in 2016 would have been 26.0% (= 1 -exp(-0.231)) higher. As shown in Table 1 , the total number of DALYs lost in 2016 was 8.896 million, so we estimate that drugs launched during 1986-2001 reduced the number of DALYs lost in 2016 by 2.31 million. If those drugs had not been launched, the total number of DALYs lost in 2016 would have been 11.21 million. Similar calculations based on the YLL and YLD estimates imply that almost all (93%) of the reduction in DALYs was due to a reduction in YLL.
As noted earlier (see Table 1 ), the age-standardized DALY rate declined by 14.4% between 2000 and 2016. The estimate of the model in row 16 of Table 2 indicates that, if no drugs had been launched during 1986-2001, the age-standardized DALY rate would not have declined; it might even have increased. 25 Fig. 6 compares actual % declines in Fig. 3 . Estimates of β k parameters of eq. (4). 25 The intercept (δ′) of that model is positive but not statistically significant (estimate = 0.046; t-value = 1.03; p-value = .305). The increase in obesity and age-standardized DALY, YLL, and YLD rates, 2000-2016 to estimated % declines attributable to drugs launched during 1986-2001. According to unpublished IQVIA data, expenditure in Canada in 2016 on drugs launched during 1986 -2001 This expenditure estimate, along with our estimate of the reduction in DALYs lost, implies that pharmaceutical expenditure per DALY gained in 2016 from drugs launched during 1986-2001 was 2842 USD (= 6.57 billion USD/2.31 million DALYs). 27 As noted by Bertram et al. (2016) , authors writing on behalf of the WHO's Choosing Interventions that are Cost-Effective project (WHO-CHOICE) suggested in 2005 that "interventions that avert one DALY for less than average per capita income for a given country or region are considered very cost-effective; interventions that cost less than three times average per capita income per DALY averted are still considered cost-effective." Canada's per capita GDP was 42,158 USD in 2016, so these estimates indicate that the new (footnote continued) diabetes prevalence might have caused the age-standardized DALY rate to increase.
26 This is about 1/3 (32%) of IQVIA's estimate of total pharmaceutical expenditure in 2016 (20.51 billion USD). IQVIA's estimate of total pharmaceutical expenditure is 17% lower than the estimate of 2016 expenditure on prescribed drugs reported in the Canadian Institute for Health Information's National Health Expenditure Database: 24.76 billion USD (= 32.15 billion CAD at a 0.77 USD/CAD exchange rate). But IQVIA's estimate is only 6% lower than the estimate of 2016 total pharmaceutical sales reported in the OECD Health Statistics Database: 21.82 billion USD (= 28.33 billion CAD at a 0.77 USD/CAD exchange rate).
27 A recently-published study (Lichtenberg (2019) ) of 66 diseases in 27 countries during the period 2000-2013, which employed a 3-way fixed-effects design that controlled for the average decline in the YLL rate in each country and from each disease, yielded a virtually identical cost-effectiveness estimate. drugs launched during 1986-2001 were very cost-effective, overall. Several considerations suggest that 2842 USD may be an overestimate of the true net cost in 2016 per DALY of drugs launched during 1986-2001. First, that estimate is based on drug cost measured at invoice price levels; rebates and discounts are not reflected. 28 Second, a previous study based on U.S. data (Lichtenberg (2014c) ) showed that about 25% of the cost of new drugs is offset by reduced expenditure on old drugs. 29 Third, our estimates indicated that, if no drugs had been launched during 1986-2001, the average length of 2016 hospital stays would have been about 16% higher. This suggests that hospital expenditure might have been 16% higher. According to the Canadian Institute for Health Information (2017), hospital expenditure in 2016 was 51.30 billion USD (= 66.63 billion CAD at a 0.77 USD/CAD exchange rate), so hospital expenditure might have been 8.21 billion USD (= 16% * 51.30 billion USD) higher. The reduction in hospital expenditure due to shorter average length of stay may have been larger than the expenditure on the drugs responsible for shorter hospital stays.
Summary
In this study, we performed an econometric assessment of the role that pharmaceutical innovation-the introduction and use of new drugs-has played in reducing the burden of disease in Canada, by investigating whether diseases for which more new drugs were launched had larger subsequent reductions in disease burden. Since utilization of a drug reaches a peak about 12-14 years after it was launched, we allowed for considerable lags in the relationship between new drug launches and the burden of disease.
We analyzed the impact of new drug launches on a comprehensive measure of disease burden-the age-standardized disability-adjusted life-years lost (DALY) rate-and on its two components: the age-standardized years of life lost (YLL) and years lost to disability (YLD) rates. We also analyzed the impact of new drug launches on the number of hospital discharges and on the average length of hospital stays.
We found that the number of DALYs lost is significantly inversely related to the number of drugs that had ever been launched 9-20 years earlier, and that the number of YLLs is significantly inversely related to the number of drugs that had ever been launched 11-20 years earlier. The launch of a drug had the largest (most negative) impact on the number of DALYs and YLLs 15 years after it was launched.
The estimates indicated that if no drugs had been launched during 1986-2001, the age-standardized DALY rate would not have declined between 2000 and 2016; it might even have increased. Almost all (93%) of the reduction in DALYs was due to a reduction in YLL. The estimates implied that new drug launches during 1986-2001 reduced DALYs in 2016 by 21%, reduced YLLs in 2016 by 28%, and reduced YLDs in 2016 by 3%.
We estimated that drugs launched during 1986-2001 reduced the number of DALYs lost in 2016 by 2.31 million. Expenditure in 2016 on drugs launched during 1986-2001 per DALY gained in 2016 from those drugs was 2842 USD. Interventions that avert one DALY for less than average per capita income for a given country or region are generally considered to be very cost-effective; Canada's per capita GDP was 42,158 USD in 2016, so our estimates indicate that the new drugs launched during 1986-2001 were very cost-effective, overall.
Due to data limitations, we were unable to control for non-pharmaceutical medical innovations. Evidence from previous studies suggests that this is unlikely to cause significant bias in our estimates, because (1) the vast majority (88%) of private U.S. biomedical research funding came from pharmaceutical and biotechnology firms, and (2) non-pharmaceutical medical innovation does not appear to be positively correlated across diseases with pharmaceutical innovation. But, arguendo, suppose that drugs launched during 1986-2001 reduced the number of DALYs lost in 2016 by half as much as we estimated: by 1.155 million, instead of 2.31 million, and that the other half was due to new medical devices. Then 2016 expenditure on those drugs per 2016 DALY reduction would be twice as high as we estimated: $5684, instead of $2842. Even this higher figure would indicate that the new drugs launched during 1986-2001 were very cost-effective in 2016.
Moreover, 2842 USD may be an overestimate of the true net cost in 2016 per DALY of drugs launched during 1986-2001. A previous study based on U.S. data showed that about 25% of the cost of new drugs is offset by reduced expenditure on old drugs. Also, our estimates indicated that, if no drugs had been launched during 1986-2001, the average length of 2016 hospital stays would have been about 16% higher. The reduction in hospital expenditure due to shorter average length of stay may have been larger than the expenditure on the drugs responsible for shorter hospital stays. WHO (2018)). 29 That study also demonstrated that pharmaceutical innovation has reduced work-loss and school-loss days.
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